Risk Detection in Neuroscience Trials: Are You Missing Early Warning Signs?

Meet Our Speakers:

Andreas Schreiner, M.D.
Senior Vice President, Medical Affairs, Neuroscience and Analgesia

Adam Simmons
Executive Director, Program Strategy, Neuroscience

Consulting

Three Keys to Preparing Effective Pre-IND Meeting Questions

By Premier Consulting

May 2, 2024

Medical and Regulatory Affairs

FDA’s Final Rule on LDTs and Its Impact on Clinical and Regulatory Professionals

By Charles Chrisawn

April 30, 2024

Enhancing Clinical Trial Accessibility – Bringing Oncology Trials to Patients

Listen Now